Pfizer aims to begin marketing Nyvepria in the European Union in the first quarter of 2021.
The European Commission (EC) has approved a Pfizer biosimilar for pegfilgrastim (Nyvepria), paving the way for marketing to begin. The drug is indicated for the reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients who have received chemotherapy treatment. The company said marketing is expected to begin in the first quarter of 2021.
The addition of Nyvepria will make 8 biosimilar pegfilgrastims available in the EU market vs 4 in the United States. Nyvepria received FDA approval for marketing in June of 2020. Febrile neutropenia is a common adverse event associated with cancer treatments and leaves patients vulnerable to infections, Pfizer explained in a statement about the EC approval.
“The development of febrile neutropenia in people living with cancer who are undergoing chemotherapy can be a very serious complication,” said Paul Cornes, MD, an oncologist and member of the continuing medical education program of the European Association of Hospital Pharmacists and core lecturer for the European School of Oncology. “The EC approval of Nyvepria provides clinicians with an alternative long-acting option that can help prevent infections.”
Pfizer said Nyvepria, the company’s sixth approved oncology biosimilar and third approved supportive care biosimilar in Europe, was approved following submission of comprehensive data package and on the basis of “totality of evidence” that demonstrated equivalence to the reference drug pegfilgrastim.
The reference product for pegfilgrastim is Amgen’s Neulasta, and this was separately approved by the FDA and the EC in 2002. Pegfilgrastim biosimilars began to appear on the European market in 2018, and there is now a crowded market for these products—in addition to Nyvepria, there are 7 pegfilgrastim biosimilars available for sale in Europe: Fulphila (2018, Mylan), Pelgraz (2018, Accord Healthcare), Pelmeg (2018, Cinfa Biotech), Udenyca (2018, Coherus), Ziextenzo (2018, Sandoz), Grasustek (2019, Juta Pharma), and Pegfilgrastim Multipharma (2019, Multipharma Biologics).
A report early this year described pegfilgrastim biosimilars as having achieved a 42% market share in Europe vs 29% in the United States, where Neulasta competes alongside Ziextenzo, Udenyca, Fulphia, and Nyvepria.
However, Amgen’s patented Neulasta Onpro wearable injector device for Neulasta has taken an increasing share of the market from biosimilar versions, which must be administered inside the clinic; and providers and industry observers say the convenience of Onpro for treatment of patients during the pandemic, when office visits have declined, has contributed to the growing use of this product. Neulasta Onpro had a 55% share of the US market for pegfilgrastim during the third quarter of 2020. Onpro was approved for use in the EU market in 2018.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.